Avant Genomics, Inc.

Avant Genomics, based in the US, is a biotechnology firm focused on innovative automated liquid biopsy technologies for blood-based cancer detection. Avant Genomics was founded in 2023 by co-founders Rachelle Turiello and Renna Nouwairi in Charlottesville, US, specializing in automated liquid biopsy sample preparation for cancer diagnostics. In May 2026, Avant Genomics raised approximately USD 3 million in venture funding from investors TitletownTech Ventures, Halyard Ventures, Virginia Venture Partners, CAV Angels, and Global Impact Fund. Avant Genomics specializes in the development of automated liquid biopsy sample preparation platforms designed to facilitate blood-based cancer detection.

Their core offerings include an enclosed fluidic cartridge system and benchtop instruments that streamline the preparation process, reducing the number of hands-on steps from dozens to just two: loading the sample and removing the cartridge. This system integrates DNA enrichment and purification within a closed, 12-plex cartridge, targeting improvements in DNA recovery and consistency while achieving substantial cost savings compared to conventional methods. Avant Genomics serves clinical laboratories and research institutions across North America and Europe, addressing challenges such as workflow bottlenecks, high operational costs, and the need for reliable cancer detection methods. Avant Genomics generates revenue through direct sales and partnerships with laboratories and healthcare institutions utilizing their automated liquid biopsy systems.

This includes sales of benchtop instruments and fluidic cartridges, typically under specific pricing plans based on order volume or subscription models for ongoing supply. The company's products enhance the efficiency and accuracy of cancer diagnostics, targeting hospitals, diagnostic labs, and research facilities as its client base. The company will use the May 2026 funding to advance development of its automated platform, support research and development, accelerate manufacturing, and expand hiring.